In solid tumor xenograft models using, for example, the breast cancer cell lines MDA-MB-231 and 2LMP TNBC, anti-tumor activity was demonstrated when the DR5 monoclonal antibody, CTB-006, was used together with the IAP antagonist APG-1387 (Li et al., 2021). Here, TNFRSF10B is linked to breast cancer.